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Oncostatin M (OSM) is released together with type I interferon (IFN) by activated dendritic cells, suggesting
a concerted action of these cytokines in the biological response against infection. We found that OSM increases
the antiviral effect of IFN- in Huh7 hepatoma cells infected with hepatitis A or hepatitis C virus and
synergizes with IFN- in the induction of antiviral genes. The combination of OSM and IFN- led to
upregulation of both STAT1 and STAT3 together with intense and prolonged activation of STAT1, STAT3, and
Jak1. OSM with or without IFN- also activated p38 mitogen-activated protein kinase, which is known to
enhance transcription of IFN--inducible genes. Interestingly, OSM combined with IFN- strongly induced
immunoproteasome genes and other genes involved in antigen processing and presentation. Moreover, OSM,
alone or in combination with IFN-, upregulated relevant innate immunity molecules and increased the
expression of intracellular adhesion molecule 1 and interleukin-15 receptor alpha (IL-15R) in liver cells.
Hepatoma cells transfected with a plasmid encoding a viral antigen were able to activate effector T cells when
pretreated with IFN- plus OSM but not with each cytokine separately. Also, OSM, more than IFN-,
augmented the ability of Huh7 cells to transpresent IL-15 to responding lymphocytes and increased the
immunostimulatory activity of liver epithelial cells by presenting a short viral peptide to sensitized cytotoxic
T cells. In conclusion, OSM enhances the antiviral effects of type I interferon and cooperates with it in the
induction of adaptive immune responses to pathogens. These findings may have therapeutic implications.
Oncostatin M (OSM) is a member of the interleukin-6
(IL-6) cytokine family, which includes IL-6, cardiotrophin-1
(CT-1), IL-11, leukemia inhibitory factor (LIF), and ciliary
neurotrophic factor (1–3). All of them share a common signal-
transducing receptor component called gp130 (13, 19, 23). In
humans, OSM binds to a heterodimer composed of gp130 and
LIFR, which is common to OSM and LIF. OSM also binds
with high affinity to a receptor formed by gp130 and the OSM
receptor (OSMR), which specifically recognizes OSM (1).
Binding of OSM to its receptor complex activates Janus ty-
rosine kinases (Jak1, Jak2, and Tyk2) as well as STAT1 and
STAT3 (19).
OSM is produced by activated monocytes and macrophages
(31, 52), and it is also secreted by dendritic cells in response to
pathogen-associated molecular patterns (47). It has also been
shown that neutrophils produce and release OSM upon stim-
ulation with lipopolysaccharide (LPS) or granulocyte-mono-
cyte colony-stimulating factor (4, 18, 20). OSM, as IL-6, is
known to enhance the synthesis of acute-phase proteins by
hepatocytes (25). Altogether, these findings indicate that OSM
might be a player of innate immunity. However, its role in the
defense against pathogens and in the orchestration of immune
responses has not yet been defined.
Type I interferons (IFN-/) constitute a group of closely
related molecules fulfilling essential functions in the early re-
action against infectious agents. IFN-/ are rapidly produced
in response to viral infections and are also induced by bacteria
(2). IFN-/ interacts with a single receptor composed of two
subunits, IFNAR1 and IFNAR2 (2). Signal transduction is
mediated by Jak1 and Tyk2, which phosphorylate and activate
STAT1, STAT2, and STAT3 proteins (2, 8). STAT1 and
STAT2 dimerize and together with ISGF3G form the ISGF3
transcription factor complex. In addition, activated STAT1
and STAT3 can form homodimers or STAT1-STAT3 het-
erodimers, which also drive gene transcription (54). Binding
of IFN-/ to its receptor activates the expression of a
variety of genes that interfere with viral replication and
induce an antiviral state in neighboring noninfected cells.
This effect, together with the enhancement of the cytotoxic
activity of NK cells and macrophages (16), makes IFN-/ a
master player in innate immunity.
Type I IFNs are instrumental in linking natural and adaptive
immune responses (16). In particular, IFN- is an efficient
Th1-biasing cytokine which is necessary for priming and cross-
priming CD8 T cells by antigen-presenting cells (28) and for
the generation and activity of cytotoxic T lymphocytes (CTL)
(5). Since both OSM and IFN- activate Jak/STAT pathways
after binding to their specific receptors and the two cytokines
are induced in response to infection, we hypothesized the ex-
istence of functional interactions between them. Here we show
that OSM acts at the interphase of innate and adaptive immu-
* Corresponding author. Mailing address: Division of Hepatology
and Gene Therapy, Center for Applied Medical Research, and Uni-
versity Clinic, University of Navarra, Avda. Pio XII 55, 31008 Pam-
plona, Navarra, Spain. Phone: 34-948194700 or 34-296785. Fax: 34-
948194717. E-mail for E. Larrea: elarrea@unav.es. E-mail for J.
Prieto: jprieto@unav.es.
 Published ahead of print on 21 January 2009.
3298
 o
n
 August 22, 2012 by Universidad de Navarra
http://jvi.asm.org/
D
ow
nloaded from
 
nity, enhancing the antiviral effect of IFN- and stimulating
the processes of antigen processing and presentation in liver
epithelial cells. In addition, OSM activates the immunostimu-
latory functions of liver epithelial cells and increases their
ability to transpresent IL-15 to the effector lymphocytes. These
novel properties of OSM could be exploited in the clinic to
enhance the antiviral and immunostimulatory effects of IFN-
-based therapies.
MATERIALS AND METHODS
DCs. Dendritic cells (DCs) were generated as described previously (43). DCs
(105/well) were seeded in 96-well plates and stimulated with 1 g/ml of LPS for
different times (from 0 to 40 h) or 20 g/ml of poly(I-C) for 8 and 24 h. The
antiviral activity of IFN was measured in supernatants of DCs after 24 h of LPS
or poly(I-C) stimulation as described previously (27). Protein levels of OSM were
determined in an enzyme-linked immunosorbent assay (ELISA; R&D Systems)
according to the manufacturer’s instructions.
Antiviral assays. Antiviral assays were performed in Huh7 cells transfected
with full-length hepatitis C virus (HCV) replicon (26, 38) and in Huh7 cells
infected with hepatitis A virus (HAV) (4.6  103 PFU/ml). These Huh7 cells
were seeded onto 24-well plates (2  104 cells/well) in Dulbecco’s minimum
essential medium (Gibco) supplemented with 10% fetal bovine serum, penicillin
(100 IU/ml), and streptomycin (100 g/ml). Twenty-four h later, cells were left
untreated or treated with 20 ng/ml of IL-6, CT-1, or OSM (R&D Systems) plus
different amounts of IFN-2 (from 0 to 100 IU/ml; Sicor Biotech) for 72 h.
RNA extraction and real-time RT-PCR. Total RNA extraction was performed
using a nucleic acid purification lysis solution (Applied Biosystems) and the
semiautomated ABI Prism 6100 Nucleic Acid PrepStation system (Applied Bio-
systems). Real-time reverse transcription-PCR (RT-PCR) was performed as
described previously (26) using specific primers for each gene.
Western blot assays. A total of 1.5  104 Huh7 or HepG2 cells were seeded
onto six-well plates. After 24 h, cells were left untreated or treated with IFN-2
(50 IU/ml), OSM (20 ng/ml), or IFN-2 (50 IU/ml) plus OSM (20 ng/ml). At
different time points, cells were washed with phosphate-buffered saline and
collected in 150 l of protein loading buffer (62.5 mM Tris-HCl, pH 6.8, 10%
glycerol, 5% 2-mercaptoethanol, 2% sodium dodecyl sulfate, 0.006% bromo-
phenol blue). Western blotting was performed (26) using the following anti-
bodies: anti-phospho-STAT1tyr701, anti-phospho-STAT3tyr705, anti-phospho-
JAK1tyr1022/1023, anti-phospho-Tyk2tyr1054/1055, anti-phospho-p38thr180/tyr182
mitogen-activated protein kinase (MAPK), and anti-rabbit immunoglobulin
G (IgG)–horseradish peroxidase conjugate (all from Cell Signaling Technol-
ogy); anti-STAT3, anti-Tyk2, anti-STAT2, anti-phospho-STAT2tyr689 anti-
bodies (Upstate Biotechnology); anti-STAT1 and anti-p38 MAPK antibodies
(Santa Cruz Biotechnology), anti-Tap1, anti-ICAM-1, anti-PSMB9, anti-
OSMR, and anti-B2M (Abcam); anti-actin and anti-mouse IgG–horseradish
peroxidase–linked antibodies (Sigma-Aldrich); anti-HCV core (kindly pro-
vided by Martinez-Anso, CIMA, Pamplona, Spain).
Microarray analysis. Huh7 cells were seeded at 1  106 cells/plate in Dulbec-
co’s minimum essential medium plus 10% fetal bovine serum. After 18 h, cells
were left untreated or treated with IFN-2 (50 IU/ml), OSM (20 ng/ml), or
IFN-2 (50 IU/ml) combined with OSM (20 ng/ml). Three days later, cells were
harvested in 1 ml of TRIzol reagent (Invitrogen). The experiments were per-
formed in quadruplicate. Samples were then processed following Affymetrix
recommendations and cRNA was hybridized to the Affymetrix human U133A 2.0
array. Both background correction and normalization were done using the Ro-
bust Multichip average algorithm (21). After calculation of the expression for
each probe set in all the microarrays, a filtering process was performed to
eliminate low-expression-level probe sets. Applying the criterion of an expression
value greater than 16 in 17% of the samples, 17,927 probe sets were selected for
the statistical analysis. The program Linear Models for Microarray Data (45) was
used to find which probe sets showed significant differential expression under
experimental conditions. Genes affected by IFN-2, OSM, or the combination of
IFN-2 plus OSM treatments were identified as significant based on a B statistic
cutoff (B 0). Genes were selected based on a change criterion of 1.2-fold in the
following ratios: (IFN-2  OSM)/OSM and (IFN-2  OSM)/IFN-2. Func-
tional categories were studied by using Ingenuity Pathways Analysis (Ingenuity
Systems; www.ingenuity.com) and Webgestalt (55).
Antigen processing and presentation assays. Peripheral blood mononuclear
cells obtained from an HLA-A2 healthy donor were pulsed with 1 g/ml of
HLA-A2-restricted influenza A virus matrix 58–66 peptide (GILGFVFTL) for
2 h at 37°C, washed, and cultured on 24-well plates at a density of 3  106
cells/well. Three days later, IL-2 (10 U/ml) was added and cells were cultured for
an additional 5 days. On day 8, recovered cells (105/well) were cocultured in
96-well round-bottom plates with 5  104/well of the following stimulator hep-
atoma cells: (i) HepG2 cells untreated or previously treated for 4 days with
IFN-2 (50 IU/ml), OSM (20 ng/ml), or the combination IFN-2 (50 IU/ml) plus
OSM (20 ng/ml), in the presence or absence of 1 g/ml of GILGFVFTL peptide;
(ii) Huh7 cells untreated or previously treated for 3 days with IFN-2 (50 IU/ml),
OSM (20 ng/ml), or the combination and cotransfected 24 h after cytokine
addition with plasmid pLNCX encoding HLA-A2 (kindly provided by N. Aptsi-
auri, Hospital Universitario Virgen de las Nieves, Granada, Spain) and plasmid
pSV982 encoding influenza matrix protein (a gift from J. Ortín, CNB, Madrid,
Spain). Transfection (1.5  105 cells/well) was carried out using 10 mM poly-
ethylenimine (18 l; high molecular weight, pH 7; Aldrich) and plasmids (3 g
of each plasmid). Cotransfected cells treated with both cytokines and the pro-
teasome inhibitor Z-LLF-CHO (Sigma) at 1 M were also employed. In all
cases, after 24 h of coculture the supernatants were collected to measure IFN-
production by ELISA (BD Biosciences).
IL-15R activity assay. Huh7 cells were seeded and treated with IFN-2 (50
IU/ml), OSM (20 ng/ml), or the combination. Three days later, they were har-
vested and incubated for 1 hour with or without 50 ng/ml of exogenous IL-15,
washed three times, and irradiated at 15,000 cGy in a Gammacell 3000 Elan
apparatus. Then, 3  104 irradiated Huh7 cells were cocultured with 1  104
CTLL-2 cells in 96-well plates. On day 2, cells were pulsed with 0.5 Ci/well of
tritiated thymidine for 8 h and harvested, and thymidine incorporation was
measured in a scintillation counter (Topcount; Packard).
Statistical analysis. Statistical methods used were as described previously (26).
Data are means  standard deviations (SD); a P value of 	0.05 was considered
significant. To study the type of interaction between IFN-2 and the members of
the IL-6 cytokine family (IL-6, OSM, and CT-1), we performed multivariant
analyses following the method previously described (7). The type of interaction
between two molecules was fixed by the interaction index, which was calculated
as follows: I 
 d1/D1  d2/D2 (d1 and d2 are the inhibitor concentrations in the
combination, and D1 and D2 are the concentrations of the inhibitors 1 and 2 that
separately exert the same inhibition as the combination). Therefore, if I is equal
to 1 this indicates that there is no interaction and that the effect is additive. If I
is lower than 1, the combination exerts synergism, and if I is higher than 1 the
combination is antagonistic.
Microarray data accession number. The microarray data for Huh7 cells un-
treated or treated with IFN-2, OSM, or IFN-2 plus OSM have been deposited
in the GEO database under accession number GSE13046.
RESULTS
OSM is released by activated DCs and synergizes with
IFN- in the inhibition of HCV and HAV replication in he-
patic Huh7 cells. It has been already shown that DCs release
OSM upon Toll-like receptor (TLR) ligation (47). We ob-
served that incubation of DCs with LPS (a TLR4 agonist)
caused rapid upregulation of OSM mRNA, with two peaks at
1 h and 8 h and returning to basal values by 16 h. This was
accompanied by secretion of the cytokine to the extracellular
space starting at 8 h and reaching maximum levels at 24 h (Fig.
1A and B). TLR3 ligation also induced OSM and promoted its
release to the extracellular milieu, although the levels were
lower than those observed following TLR4 activation (Fig. 1C
and D). At 24 h after TLR stimulation the secretion of OSM
was accompanied by the release of type I IFN to the medium
(Fig. 1E). The simultaneous secretion of type I IFN and OSM
led us to hypothesize that these two cytokines might act in
concert in the defense against pathogens.
The induction of OSM in DCs upon TLR activation was not
accompanied by any modification in the expression of OSMR
or LIFR mRNAs. These two transcripts were maintained at
extremely low levels in DCs (Fig. 1F and G). Western blot
analysis showed that while OSMR was abundantly expressed in
cells of hepatocellular lineage, Huh7 and HepG2, this receptor
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was undetectable in resting and LPS-activated DCs (Fig. 1H),
suggesting that DC-derived OSM targets epithelial cells rather
than DCs themselves. Indeed, we found that neither the addi-
tion of OSM nor its blockade with anti-OSM antibodies mod-
ified CD80 expression nor the synthesis of IL-12 or IL-10 in
LPS-stimulated DCs (data not shown).
Because OSMR is highly expressed in cells of hepatocellular
lineage, we centered our study on the role of OSM in the
defense of liver cells against infection. We found that OSM
reduced viral load in Huh7 cells supporting HCV or HAV
replication. This antiviral activity was significantly higher than
that exerted by other members of the IL-6 superfamily,
namely, CT-1 and IL-6 (Fig. 2A and B). Importantly, the com-
bination of IFN-2 plus each one of these cytokines enhanced
the antiviral potency of IFN-2, and the mixture IFN- plus
OSM was the most effective in reducing replication of both
HCV and HAV (Fig. 2A and B). The calculation of the inter-
action index (I) of IFN-2 with OSM, CT-1, or IL-6 showed
synergism in all cases (I 	 1), but it was stronger with the
combination IFN-2 plus OSM (0.11 and 0.17 for HCV and
HAV replication, respectively). We also analyzed the levels of
HCV core protein in HCV replicon cells after incubation for 3
and 4 days with IFN-, OSM, or the combination. As shown in
Fig. 2C, OSM decreased core protein only modestly and
IFN-2 caused a marked reduction of this viral antigen, while
the combination of OSM plus IFN-2 completely abrogated
HCV core expression at day 4 of incubation.
In line with these findings we observed that OSM (and
substantially less IL-6 and CT-1) synergized with IFN-2 in the
induction of the interferon-sensitive genes OAS, ISG20, and
GBP1 in HCV- or HAV-infected Huh7 cells (Fig. 3A to F).
Notably, OSM alone upregulated some interferon-inducible
genes, such as ISG20 and GBP1. The synergisms of OSM (and
that of IL-6 and CT-1) with IFN-2 on antiviral activity and
induction of antiviral genes were observed not only with
IFN-2 but also with other IFN- subtypes, such as IFN-5
(data not shown), which is the IFN- subtype most abundantly
expressed in the liver (3).
Jak/STAT signaling in Huh7 cells treated with IFN- and/or
OSM. To analyze cell signaling mechanisms activated by the
combined effect of OSM and IFN-, we performed immuno-
blotting analysis of Jak/STAT proteins in Huh7 cells treated
for 1, 3, 24, 48, and 72 h with IFN-2, OSM, or both. As shown
in Fig. 4, STAT2 was only activated by IFN-2 or by its com-
bination with OSM being transient and not detectable by 24 h.
Similarly, STAT1 was strongly phosphorylated by IFN-2 at 1
and 3 h but its activation was no longer present at 24 h.
However, IFN-2 caused an increase of total STAT1 protein
which was apparent from 24 h onwards. OSM activated STAT1
at 1 h, and the signal was faint during the following time points
FIG. 1. DCs release OSM and type I IFN upon TLR ligation but lack OSM receptors, as opposed to liver epithelial Huh7 and HepG2 cells.
The transcriptional expression of OSM (A), OSMR (F), and LIFR (G) was analyzed by quantitative RT-PCR in monocyte-derived DCs treated
with LPS (TLR4 ligand) for the indicated periods of time, and the release of OSM to the medium in the same time periods was determined by
ELISA (B). A Western blot assay for OSMR was performed in Huh7 and HepG2 cells and in monocyte-derived DCs stimulated or not with LPS
for 24 h (H). (C to E) Comparison of the ability of TLR4 (LPS) and TLR3 [poly(I-C)] ligands to stimulate OSM expression (C) and release to
the medium (D) and type I IFN secretion (E). Values are means  SD of three experiments performed in quintuplicate.
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but lasted 72 h. OSM also increased, albeit moderately, the
levels of total STAT1 protein. When IFN-2 was combined
with OSM we observed an additive effect of the two cytokines,
resulting in increased levels of total STAT1 and prolonged
activation of this molecule, leading to a strong activation signal
of STAT1 lasting up to 72 h. Relating STAT3, IFN-2 caused
only a mild and transient activation of the molecule which was
no longer detectable after 1 h. In contrast, OSM alone and the
combination OSM plus IFN-2 induced a rapid and very ro-
bust activation of STAT3 that persisted at 72 h. This was
accompanied by increased levels of STAT3 protein from 24 h
onwards. Moreover, OSM, alone or in combination with IFN-
2, caused stronger and more prolonged activation of Jak1
than when using IFN-2 alone (Fig. 4A). It seems possible that
the longer and stronger activation of Jak1, STAT1, and STAT3
caused by OSM plus IFN-2 might facilitate durable formation
of STAT1 and STAT3 homodimers and heterodimers and
enhanced expression of IFN--responsive antiviral genes.
Since activation of p38 MAPK has been shown to facilitate
IFN--driven gene expression through ISRE and GAS ele-
ments (36), we also analyzed the effect of both cytokines in the
activation of this signaling molecule. We found that in Huh7
cells IFN- failed to induce p38 phosphorylation while OSM
with or without IFN- caused marked p38 activation for at
least 72 h (Fig. 4B). This effect on p38 might contribute to
enhance the expression of IFN--sensitive genes when both
cytokines are used in combination.
Microarray analysis of genes induced by IFN- and/or
OSM. To gain insight into the transcriptional program acti-
vated by the joint action of IFN-2 plus OSM, we studied the
transcriptome of Huh7 cells incubated for 72 h in basal me-
dium or in the presence of IFN-2 (50 IU/ml), OSM (20
FIG. 2. Antiviral effect of cytokines of the IL-6 family (IL-6, CT-1, and OSM) used alone or in combination with different doses of IFN-2
in cells transfected with full-length HCV replicon or HAV infected. Cells were treated with the cytokines (or were left untreated) for 72 h.
HCV-RNA and HAV-RNA were determined by quantitative RT-PCR (A and B). HCV core protein was estimated by Western blotting (C).
Values are means  SD of three experiments performed in triplicate. *, P 	 0.05 versus IL-6, CT-1, and OSM; **, P 	 0.05 versus CT-1
and OSM; #, P 	 0.05 versus IL-6 and CT-1.
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ng/ml), or both. After functional analysis studies with the genes
differently expressed, we found an enrichment of biological
categories that included antiviral genes, genes involved in an-
tigen presentation, and genes encoding key immunoregulatory
factors (Fig. 5). Validation of these genes was performed by
quantitative RT-PCR after RNA extraction from Huh7 cells
treated with IFN-2, OSM, or both for 24, 48, and 72 h.
Validated genes could be grouped into two clusters: (i) genes
sensitive or not to IFN- which showed little or no change with
OSM alone but manifested vigorous upregulation with the
combination treatment (Fig. 5); (ii) genes that were induced by
OSM as well as by the combination of the two cytokines (Fig.
5). The positive interaction of OSM with type I IFN in the
induction of antiviral genes and other immunoregulatory mol-
ecules was observed not only with IFN- but also with IFN-
(data not shown).
Cluster A comprised mainly antiviral genes and genes
implicated in antigen processing and presentation. Antiviral
genes in this cluster include ZC3HAV1, TRIM22, Mx1, IFI35,
TLR3, and ISGF3G, in addition to GBP1, ISG20, and OAS, as
mentioned above (Fig. 3). Mx proteins bind viral ribonucleo-
protein structures and block replication of viral RNA (9).
TRIM22 and ZC3HAV1 have been implicated in the defense
against retroviruses and alphaviruses (30, 56). TLR3 is local-
ized in endosomes acting as a sensor of virus-derived double-
stranded RNA that mediates type I IFN induction (22).
ISGF3G contributes to efficient transcription of IFN-/-sen-
sitive genes (51).
Cluster B included genes encoding molecules relevant to
innate immunity and genes implicated in lymphocyte activation
and expansion, as well as specific antiviral genes and genes
involved in antigen presentation.
OSM induces key players of innate immunity. OSM was
able to directly induce a variety of molecules that are essential
in the natural defense against infection, including MYD88,
S100A9, ULBP2, IL-32, IRF1, and GBP2 and the chemokine
genes CXCL1, CXCL2, and CXCL3 (several of these genes
were more intensely induced with OSM plus IFN- than with
OSM alone) (Fig. 6). MYD88 is the adapter protein for TLR2,
-4, -5, -7, -8, and -9, and S100A9 contributes to MYD88 trans-
location to the TLR4-MD2 complex, thus enhancing TLR4
signaling (53). IL-32 is a proinflammatory cytokine that acti-
vates monocytes/macrophages (11). ULBP2 is a stress-induced
molecule and a ligand for NKG2D that activates NK cells and
provides costimulation for T cells by acting as a danger signal
to alert the immune system of the presence of DNA damage or
FIG. 3. Effect of cytokines of the IL-6 superfamily (IL-6, CT-1, and OSM) used alone or in combination with different doses of IFN-2 on the
expression of antiviral genes in cells transfected with full-length HCV replicon or HAV infected. Cells transfected with full-length HCV replicon
or HAV infected were treated with the cytokines (or were left untreated) for 72 h. Gene expression levels of OAS (A and D), ISG20 (B and E),
and GBP1 (C and F) were determined by quantitative RT-PCR. Values are means  SD of three experiments performed in triplicate. *, P 	 0.05
versus IL-6, CT-1, and OSM; **, P 	 0.05 versus CT-1 and OSM; ***, P 	 0.05 versus OSM; #, P 	 0.05 versus IL-6 and CT-1; ##, P 	 0.05
versus IL-6.
3302 LARREA ET AL. J. VIROL.
 o
n
 August 22, 2012 by Universidad de Navarra
http://jvi.asm.org/
D
ow
nloaded from
 
intracellular infection (15). IRF1 is a factor known to enhance
type I IFN production upon TLR ligation (34).
Upregulation of molecules involved in antigen processing
and presentation by the combined effect of OSM and IFN- or
by OSM alone. As previously indicated, a group of genes en-
coding molecules with essential functions in antigen processing
and presentation were strongly upregulated in Huh7 cells
treated with OSM plus IFN-2. These genes include the fol-
lowing: (i) members of the ubiquitin-immunoproteasome sys-
tem, UBE2L6, PSMB8, and PSMB9, which are implicated in
the generation of peptides from cytosolic proteins; (ii) trans-
porters of peptides into the endoplasmic reticulum for associ-
ation with major histocompatibility complex class I molecules,
namely, TAP1 and TAP2; (iii) HLA class I genes, particularly
HLA-B and HLA-C; and (iv) B2M, which encodes 2-micro-
globulin, an essential molecule for stable expression of class I
molecules on cell surfaces (41) (Fig. 7A to H). HLA-A, which
shows high basal expression, was also upregulated by the com-
bination treatment but to a lesser extent than HLA-B and
HLA-C (data not shown). OSM per se was also able to induce
other genes which are critical for antigen presentation, such as
TAPBP (Fig. 7I), whose gene product mediates the interaction
between TAP1 and HLA class I (41).
Western blot analysis of PSMB9 and TAP1 in Huh7 cells
demonstrated that treatment with IFN-2 plus OSM induced
the expression of these molecules at day 3 of incubation with
persisting strong overexpression at day 4, while each cytokine
alone caused only a mild elevation of the same proteins (Fig.
7J). In addition, B2M protein was upregulated by IFN-2, and
to a lesser extent by OSM, at day 3 but required the combined
action of IFN-2 plus OSM to be expressed at high levels on
day 4 (Fig. 7J).
These results indicate that the combination of IFN-2 and
OSM strongly stimulates in liver epithelial cells the functional
chain responsible for the generation and presentation of anti-
genic peptides to the executors of the adaptive immune re-
sponse. This effect may be relevant for immune clearance of
virus-infected cells.
OSM increases the immunostimulatory function of Huh7
cells and their ability to transpresent IL-15. We also found
that OSM induces in Huh7 cells genes that encode molecules
favoring activation and expansion of lymphocytes, namely,
ICAM-1, IL-15R, and IL-7 (Fig. 8A to C). Western blot anal-
ysis indicated that OSM alone or in combination with IFN-2
upregulated ICAM-1 with a pattern of multiple bands consis-
tent with hyperglycosylation (Fig. 8D), a modification that has
been reported to be associated with higher immunostimulatory
activity of the protein (10).
Another relevant molecule conferring immunostimulatory
properties to epithelial cells is IL-15R, which is essential for
FIG. 4. Jak/STAT signaling pathway and p38 MAPK activation in Huh7 cells treated with IFN-2, OSM, or the combination. (A) Represen-
tative Western blot analysis of phosphorylated and total protein levels of STAT1, STAT2, STAT3, Tyk2, and Jak1 in Huh7 cells cultured in medium
alone or in the presence of IFN-2, OSM, or IFN-2 plus OSM during 1, 3, 24, 48, and 72 h of incubation. (B) Representative Western blot analysis
of phosphorylated and total protein of p38 MAPK levels in Huh7 cells untreated or treated with IFN-2, OSM, or IFN-2 plus OSM during 1,
3, 24, 48, and 72 h. Actin levels are shown as a loading control.
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efficient transpresentation of IL-15 to CD8 T cells. To ascer-
tain the role of OSM in boosting the expression of functional
IL-15R we studied the effect of OSM, IFN-2, or OSM plus
IFN-2 on the ability of IL-15-pulsed Huh7 cells to sustain the
proliferation of CTLL-2 cells (an IL-15-responsive cell line).
As depicted in Fig. 8E, OSM alone or in combination with
IFN-2 caused significant stimulation of CTLL-2 proliferation,
while cell growth was similar with all forms of treatment in the
absence of IL-15. Importantly, OSM was more potent than
IFN- in enhancing IL-15 transpresentation by the epithelial
cells to the responding lymphocytes (Fig. 8E).
We further investigated whether OSM alone or in combina-
tion with IFN-2 could increase the immunostimulatory activ-
ity of liver epithelial cells. In two different sets of experiments
we used hepatoma cells either pulsed with the short peptide
GILGFVFTL or transfected with a plasmid encoding influenza
A virus matrix to stimulate lymphocytes specific for GILGFV
FTL, which is an HLA-A2-restricted epitope from the influ-
enza A virus matrix. In these experiments hepatoma cells had
been previously treated with OSM, IFN-2, or the combina-
tion or had not received any previous treatment. In the first
experiment HepG2 cells were employed, as they are HLA-
A2, and were shown to respond to OSM with upregulation of
genes involved in antigen presentation (such as B2M) and
immunostimulation (such as ICAM-1 and IL-15R) in the
same manner as Huh7 cells (data not shown). We found that
pretreatment with OSM or the combination OSM plus IFN-2
enhanced the ability of peptide-pulsed HepG2 cells to stimu-
late the production of IFN- by CTL more efficiently than
when using IFN-2 alone (Fig. 8F). In the second experiment,
we used Huh7 cells transfected with two plasmids, one encod-
ing the influenza A virus matrix protein and the other HLA-
FIG. 5. Affymetrix microarray of Huh7 cells that received no treatment or were treated for 72 h with IFN-2, OSM, or the combination. Control
and treatment groups were analyzed in quadruplicate. Columns represent the specific treatments and rows represent individual genes. Genes
upregulated by the combination therapy at levels higher than that by each cytokine in isolation are represented in blue (cluster A), and genes
upregulated by OSM alone (or plus IFN-) are represented in brown (cluster B). All genes in the figure have been validated by quantitative
RT-PCR. Next to the array a color code indicates the gene function category.
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FIG. 6. OSM upregulates genes which participate in the natural defense against infection. The transcriptional expression levels of
MYD88 (TLR adapter molecule) (A), S100A9 (modulator of TLR function) (B), ULBP2 (ligand for NKG2D that activates NK cells) (C),
IL-32 (proinflammatory molecule that activates macrophages) (D), IRF1 (factor that induces type I interferon production) (E),
GBP2 (molecule with antiviral activity) (F), and the chemokine genes CXCL1/2 and CXCL3 (G and H) were determined by quantitative
RT-PCR in untreated Huh7 cells or cells treated for the indicated periods of time with IFN-2, OSM, or the combination. Values are
means  SD of three experiments performed in quintuplicate. *, P 	 0.05 versus untreated, IFN-2, and OSM; #, P 	 0.05 versus untreated
and IFN-2.
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A2. Higher IFN- production by influenza virus-specific effec-
tor lymphocytes was observed when target cells had been
previously treated with OSM plus IFN-2 than when using
untreated cells or cells treated with IFN-2 or OSM alone
(Fig. 8G). The enhancement of lymphocyte response by treat-
ing the target cells with IFN-2 plus OSM was abolished by a
proteasome inhibitor (Fig. 8G). These findings are in keeping
with our previous data showing activation of antigen process-
ing by the concerted action of the two cytokines (Fig. 7).
DISCUSSION
Our findings have characterized OSM as a new cytokine
involved in the defense of the liver against infection. This idea
is based on the following facts: (i) in liver epithelial cells OSM
increases the antiviral properties of type I IFN and induces key
players of innate immunity; (ii) in these cells OSM synergizes
with IFN- to enhance antigen processing and presentation;
and (iii) OSM augments the immunostimulatory properties of
cells of hepatocellular lineage. Taken together these data sug-
gest an important role for this cytokine in the activation of both
innate and adaptive immunity and in linking together these two
biological responses to pathogens.
As mentioned above, OSM is released by DCs and neutro-
phils upon stimulation (18, 20, 47). We found that TLR4 ac-
tivation, and to a lesser extent TLR3 stimulation, induced
OSM secretion. Although these data might indicate that bac-
terial products are more efficient than viruses in triggering
OSM release, it should be considered that TLR4 signaling may
take place in viral infections through recognition of virion
surface proteins (37) or through interaction with molecules
such as HMGB1, released by activated macrophages or dying
cells (29). Our finding that OSM and type I interferon are
secreted simultaneously upon TLR activation suggested to us a
concerted action of the two cytokines at the earlier phases of
pathogen recognition. The notion of a functional connection
between OSM and type I IFN is also consistent with the fact
that TLR4 activation (which stimulates OSM release) couples
with the induction of type I IFN via the TRIF pathway (48).
Noticeably, OSMR is scarcely expressed by either DCs (Fig.
1) or peripheral blood lymphocytes (32), while it is abundant in
cells of hepatocellular lineage. It is thus reasonable to think
that OSM exerts its effects on epithelial cells rather than on
professional antigen-presenting cells. A key observation in this
paper was the synergism of OSM and IFN- in reducing viral
replication in liver cells transfected with full-length HCV rep-
licon or infected with HAV. We have also shown that this
effect is associated with enhanced expression of several antivi-
ral genes when both cytokines are used in combination.
The differential regulation of gene expression when using
OSM plus IFN- compared with either of them alone might be
due to interactions between the respective signaling pathways
or to changes in the levels of signaling molecules and transcrip-
tion factors, caused by one of them, that influence the tran-
scriptional response to the other. Our data show that combi-
nation of IFN- and OSM leads to more intense and more
prolonged activation of both STAT1 and STAT3 in association
with higher intracellular levels of the two proteins. While ele-
vation of STAT1 protein is caused by IFN-, the augmentation
of STAT3 is due to OSM. We also found that OSM and its
combination with IFN- resulted in increased and lasting ac-
tivation of Jak1 which might contribute to maintain STAT
phosphorylation when IFN- acts together with OSM. As a
result the joint action of OSM and IFN- could favor the
formation of STAT1/STAT3 heterodimers and STAT3/STAT3
homodimers for longer times, allowing enhanced and more
durable expression of IFN--sensitive antiviral genes (40). On
the other hand, OSM alone or combined with IFN- caused
marked and sustained p38 MAPK phosphorylation. Since p38
activation has been shown to enhance transcription of IFN--
inducible genes from both ISRE and GAS elements (36), the
effect of OSM on this signaling molecule offers an additional
explanation for the observed synergism between OSM and
IFN-.
OSM might also be implicated in natural defenses against
infection because of its stimulatory effect on the expression of
relevant components of innate immunity, such as MYD88,
S100A9, IL-32, ULBP2, IRF1, and GBP2, and by its ability to
induce the expression of the chemokines CXCL1, CXCL2, and
CXCL3, which recruit inflammatory cells to the site of infec-
tion (39).
A crucial aspect in the defense against viral infections is the
ability of the infected cells to display viral peptides on the cell
membrane in the context of HLA class I molecules for pre-
sentation to primed CD8 cells. Prior to antigen presentation
by major histocompatibility complex class I molecules, cytoso-
lic antigens must be polyubiquitinated and processed to CTL
epitopes by the proteasome. It has been shown that stimulation
of the infected epithelial cell with IFN- induces a change in
the composition of the 20S catalytic core of the proteasome by
substituting 1, 2, and 5 subunits of the inner heptameric
rings by 1i (PSMB9), 2i (MELC-1), and 5i (PSMB8), lead-
ing to the formation of the immunoproteasome, which exhibits
differences in its proteolytic activity compared to the constitu-
tive proteasome (46, 49). In fact, mice lacking PSMB8 or
PSMB9 fail to process and present specific epitopes to CD8
T cells (14, 50). It has been shown recently that not only IFN-
but also IFN- can induce the expression of immunoprotea-
some subunits (44). In the present work we have demonstrated
that OSM strongly enhances the ability of IFN- to stimulate
the production of both PSMB8 and PSMB9. The synergism
FIG. 7. OSM synergizes with IFN- in the induction of genes involved in antigen processing and presentation in Huh7 cells. mRNA levels were
determined by quantitative RT-PCR for ubiquitin-conjugating enzyme UBE2L6 (A), immunoproteasome subunits PSMB8 (B), and PSMB9 (C),
transporters associated with antigen processing, TAP1 (D) and TAP2 (E), HLA class I B and C (F and G), 2-microglobulin (H), the TAP binding
protein TAPBP (I) in Huh7 cells treated for the indicated periods of time with IFN-2, OSM, or both, or left untreated. Values are means  SD
of three experiments performed in quintuplicate. A Western blot assay determined TAP1, PSMB9, and 2-microglobulin levels in Huh7 cells
treated for 3 and 4 days with IFN-2, OSM, or the combination. Actin levels are shown as a loading control (J). *, P 	 0.05 versus untreated,
IFN-2, and OSM; #, P 	 0.05 versus untreated and IFN-2.
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FIG. 8. OSM upregulates genes that stimulate adaptive immunity and enhances IL-15 transpresentation and the immunostimulatory activity of liver
epithelial cells. (A to C) Transcriptional expression of ICAM-1 (A), IL-15R (B) and IL-7 (C) in untreated Huh7 cells or cell treated with IFN-2, OSM, or both.
(D) Western blot assay for ICAM-1 in Huh7 cells treated with IFN-2, OSM, or both. (E) Proliferative activity of CTLL-2 cells (a CD8 T-cell line with IL-15
growth dependence) incubated with Huh7 cells treated for 3 days with IFN-2, OSM, or both or left untreated. (F and G) Production of IFN- by CTL sensitized
to the influenza virus peptide GILGFVFTL cocultured with HepG2 cells previously treated for 4 days with IFN-2, OSM, both, or left untreated and pulsed
with the synthetic peptide (F) or with Huh7 cells treated for 72 h with IFN-, OSM, both, or left untreated and cotransfected with a plasmid encoding HLA-A2
and a plasmid encoding influenza A virus matrix protein (G). An additional group was treated with the cytokine combination plus the proteasome inhibitor
Z-LLF-CHO. Values are means SD of three experiments performed in quintuplicate. *, P	 0.05 versus untreated, IFN-2, and OSM; #, P	 0.05 versus
untreated and IFN-2; $, P 	 0.05 versus untreated; **, P 	 0.05 versus IFN-2 plus OSM.
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OSM and IFN- also extends to the synthesis of TAP1 and
TAP2, two proteins that are critical for loading the antigenic
peptides onto HLA class I. In addition TAP1 has been shown
to participate in host resistance to infection by stimulating
IFN--producing NK cells (17). Interestingly, the immunopro-
teasome genes PSMB8, PSMB9 map between TAP1 and TAP2
on 6p21.3, and PSMB9 and TAP1 share a common promoter
(33), suggesting coordinated regulation of these functionally
related genes. It has been recently reported that PSMB9 ex-
pression is stimulated by a heterodimer formed by unphosphor-
ylated STAT1 and IRF1 (6). The regulation of PSMB9 by these
two factors explains the synergism IFN- and OSM in the
induction of this gene, since OSM upregulates IRF1 while
IFN- elevates STAT1 levels.
Consistent with the concept that OSM operates at the inter-
face between natural and adaptive immunity, we observed that
this cytokine increases mRNA and protein levels of ICAM-1 in
epithelial cells. Moreover, in OSM-treated cells Western blot
studies showed a pattern of multiple bands compatible with
ICAM-1 hyperglycosylation, which is a posttranslational mod-
ification that accrues the immunostimulatory activity of this
costimulatory protein (10). As it has been shown that the
ICAM-1–LFA-1 interaction boosts central memory CD8 T
cells (35), our findings suggest a role of OSM-activated epithe-
FIG. 9. Representative scheme illustrating the molecules highly upregulated by the combination of OSM with type I IFN (in blue) or OSM
alone (in brown) in liver epithelial cells. OSM per se or in association with type I IFN induces a chain of antiviral defense genes, including viral
sensors (TLR3), antiviral genes (OAS1, Mx1, GBP1, ZC3HAV1, and TRIM22), antigen processing genes (UBE2L6, PSMB8, PSMB9), genes
involved in antigen presentation (TAP1, TAP2, TAPBP, HLA class I, and 2-microgloblobulin), genes implicated in activation of innate immunity
(IRF1, STAT1, STAT3, MYD88, S100A9, IL-32, and ULBP2), and genes triggering adaptive immunity (ICAM-1, IL-15R, and IL-7). Ø indicates
a macrophage. OSMR is also upregulated by OSM (data not shown). PAMPs, pathogen-associated molecular patterns; DAMPs, danger-associated
molecular patterns.
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lial cells in the expansion of this cell subset which is critical for
long-term protection against infection (35). The fact that OSM
upregulates IL-7 expression (a cytokine that promotes both
CD4 and CD8 expansion [42]) and IL-15R is consistent with
the idea that OSM may be important in the stimulation of CD8
responses in viral infections. In this context the effect on IL-
15R is of considerable relevance since this receptor interacts
with high affinity with IL-15, forming stable complexes on the
cell surface for transpresentation of the cytokine to neighbor-
ing target cells, mainly CD8 memory T cells and NK cells
(12). Due to endosomal recycling, IL-15R/IL-15 complexes
may persist for long periods on the cell membrane (12), and it
has been shown that transpresented IL-15 is much more effi-
cient than soluble IL-15 in the stimulation and expansion of
antigen-experienced CD8 T cells (24). In agreement with the
observed IL-15R upregulation induced by OSM, we found
that liver epithelial cells stimulated with this cytokine, with or
without IFN-, were able to transpresent IL-15 to CD8 T
cells more efficiently than control cells or cells treated with
IFN- alone. Although IFN- was able to increase the ability
of liver cells to transpresent IL-15 to CD8 lymphocytes, the
effect of OSM was significantly higher. The stimulation of
IL-15 transpresentation is a novel contribution of OSM to
antiviral defense of the liver since it will enhance the capacity
of hepatic parenchymal cells to activate and expand cytotoxic
CD8 T lymphocytes specific for viral epitopes. The role of
OSM in boosting the immunostimulatory properties of liver
cells was confirmed by our results showing that HepG2 cells
incubated with a viral peptide were able to stimulate the pro-
duction of IFN- at higher levels when pretreated with OSM
or the combination OSM plus IFN- than when using IFN-
alone. This higher immunostimulatory ability of liver cells
treated with OSM plus IFN- was found not only when using
peptide-pulsed HepG2 cells but also when using Huh7 cells
transfected with a plasmid encoding a viral protein. This effect
was abolished by proteasome inhibitors, in agreement with
previous data showing a higher induction of genes involved in
antigen processing by the combination IFN- and OSM. Thus,
our findings show that the concerted action of IFN- and OSM
activates in liver cells the whole functional chain leading to
efficient presentation of antigenic peptides to lymphocytes
by inducing (i) UBE2L6 expression, (ii) formation of the
immunoproteasome, (iii) upregulation of TAP1, TAP2, and
TAPBP, and (iv) enhanced expression of HLA class I mol-
ecules and 2-microglobulin and upregulation of immuno-
stimulatory molecules ICAM-1, IL-7, IL-15R. A scheme
depicting the functions of genes implicated in natural and
adaptive immunity modulated by OSM and IFN- in liver
cells is presented in Fig. 9.
In conclusion, this paper describes a novel role of OSM in
the orchestration of the defense of the liver against infection.
OSM activates natural immunity and reinforces the antiviral
effects of IFN-. On the other hand, OSM may behave as a
trigger of adaptive immune responses to hepatotropic viruses
by stimulating antigen processing and presentation and by
boosting the immunostimulatory properties of hepatic epithe-
lial cells. These findings open new avenues for more efficient
antiviral therapies.
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